Lipocine Inc
lpcn.png (verkleinert auf 44%)
http://mobile.reuters.com/article/idUSFWN1JG0JY
Quelle:
https://www.sec.gov/Archives/edgar/data/1535955/...029/v469221_8k.htm
....da simma dabei das is priiima.... :)))
https://www.forbes.com/sites/arleneweintraub/2018/...gs/#2363d2d43a4c
https://www.lipocine.com/pipeline/
da muss ich Vassago beipflichten das Panel tat sich ja dagegen entschieden..
wird eine fast unmögliche Nr. am 08.Mai
The final vote came in at 6 to 13 recommending the FDA not approve the drug
https://finance.yahoo.com/news/...-lpcn-fails-convince-220728349.html
FDA sagt "Nein"
https://endpts.com/...da-shows-another-testosterone-therapy-the-door/
LPCN 1144
http://ir.lipocine.com/2019-01-17-Lipocines-NASH-Therapy-Candidate-Achieves-Meaningful-Liver-Fat-Reduction-Based-on-Interim-Results
Allerdings gibt es Kritik am Studiendesign:
"I could conduct another webinar on clinical trial red flags based solely on todays LPCN liver fat study press release. Missing patients (and too few overall), no placebo control, skewed means, arbitrary data cutoffs, etc etc. "
https://twitter.com/adamfeuerstein/status/1085877664991178753
LPCN 1144
wieder Kritik von AF:
"Not that anyone trading cares, but today’s LPCN iver fat (NASH? NAFLD? Something else?) data are worse than the data previously disclosed in January. Also, wow, so many changes to endpoint definitions. Carry on…."
https://twitter.com/adamfeuerstein/status/1105446714276761600
lpcn2.png (verkleinert auf 44%)
lpcn3.png (verkleinert auf 32%)
FDA verweigert TLANDO zum dritten Mal die Zulassung
https://endpts.com/...ir-oral-testosterone-drug-snubbed-again-by-fda/
Glückwunsch 6 Mio. $ Offering
- 12 Mio. neue Aktien zu je 0,50$ ~ 6 Mio. $
Was für schlechtes Timing vom Management. Finger weg!
https://ir.lipocine.com/...blic-Offering-Of-Common-Stock-And-Warrants
